Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 511 to 525 of 735 results for adult social

  1. Pembrolizumab for adjuvant treatment of renal cell carcinoma (TA830)

    Evidence-based recommendations on pembrolizumab (Keytruda) for adjuvant treatment of renal cell carcinoma in adults.

  2. Golimumab for the treatment of psoriatic arthritis (TA220)

    Evidence-based recommendations on golimumab (Simponi) for treating psoriatic arthritis in adults.

  3. Patiromer for treating hyperkalaemia (TA623)

    Evidence based recommendations on patiromer (Veltassa) for treating hyperkalaemia in adults.

  4. Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma (TA680)

    Evidence-based recommendations on lenalidomide (Revlimid) for maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma in adults.

  5. Dupilumab for treating severe asthma with type 2 inflammation (TA751)

    Evidence-based recommendations on dupilumab (Dupixent) for treating severe asthma with type 2 inflammation that is inadequately controlled in people 12 years and over.

  6. Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation (TA798)

    Evidence-based recommendations on durvalumab (Imfinzi) for locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation in adults.

  7. Chronic obstructive pulmonary disease in adults (QS10)

    This quality standard covers assessing, diagnosing and managing chronic obstructive pulmonary disease (COPD). It describes high-quality care in priority areas for improvement.

  8. NICE decision aid: process guide (PMG42)

    This process guide provides an overview of the key principles used for developing NICE decision aids. It ensures that robust, quality-assured decision aids for people using and providing health and social care services are developed in an open, transparent and timely way, with appropriate input from key groups

  9. Virtual reality technologies for treating agoraphobia or agoraphobic avoidance: early value assessment (HTG701)

    Early value assessment (EVA) guidance on virtual reality technologies for treating agoraphobia or agoraphobic avoidance.

  10. Helping people to connect with local communities and reduce isolation: What social and community support approaches are effective in promoting social inclusion of people with complex needs?

    communities and reduce isolation: What social and community support approaches are effective in promoting social inclusion...

  11. One-piece closed bags for colostomies: late-stage assessment (HTG754)

    Late stage assessment (LSA) guidance on one-piece closed bags for colostomies

  12. Prevalence of mental health problems:- What is the prevalence of mental health problems and associated social problems for those in contact with the criminal justice system?

    problems:- What is the prevalence of mental health problems and associated social problems for those in contact with the criminal...

  13. What is the optimal way of discharging people approaching the end of their life from hospitals back to their place of residence?

    applicable) The committee found there was very little evidence on discharging adults approaching the end of their life and transferring...

  14. Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer (TA944)

    Evidence-based recommendations on durvalumab (Imfinzi) with gemcitabine and cisplatin for treating locally advanced, unresectable, or metastatic biliary tract cancer in adults.

  15. Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma (TA857)

    Evidence-based recommendations on nivolumab (Opdivo) with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma in adults.